Assignee
TCR2 THERAPEUTICS INC
US·10 granted patents·15 pending applications·65 citations·filing 2017–2024
Top patents by PatentIndex Score
25 records- 0197US11028142B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 0296US10442849B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Oct 15, 2019·21 cites·27 claims
- 0396US10208285B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·14 cites·20 claims
- 0495US11085021B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·3 cites·27 claims
- 0593US10358474B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·9 cites·30 claims
- 0692US11242376B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Feb 8, 2022·6 cites·19 claims
- 0788US10358473B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·4 cites·30 claims
- 0888US2024301026A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0984US11965012B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·27 claims
- 1084US11377638B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 5, 2022·1 cites·19 claims
- 1179US11851491B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Dec 26, 2023·1 cites·15 claims
- 1277US2022298478A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1371US2021206827A9Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1457US2023065936A1Compositions and methods for treating cancerTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1555US2023338421A1Compositions and methods for autoimmunity regulationTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1654US2021253666A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1753US2021315933A1Compositions and methods for tcr reprogramming using target specific fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1853US2024252641A1Compositions and methods for tcr reprogramming using cd70 specific fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1952US2024117002A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2052US2021361704A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2152US2023069322A1Compositions and methods for gamma delta tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2252US2022362295A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2351US2022347214A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2449US2021079057A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2547US2021187022A1Engineered t cells for the treatment of cancerTCR2 THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →